Skip to content
Subscriber Only
Opinion
Max Nisen

Diabetes Is Officially the Messiest Drug Market

A crowded space gets more so as the FDA approves Pfizer/Merck's Steglujan.
A monitor displays signage for Pfizer Inc., Eli Lilly and Co., AbbVie Inc. and Merck & Co Inc. on the floor of the New York Stock Exchange (NYSE) in New York, U.S., on Monday, March 13, 2017.

A monitor displays signage for Pfizer Inc., Eli Lilly and Co., AbbVie Inc. and Merck & Co Inc. on the floor of the New York Stock Exchange (NYSE) in New York, U.S., on Monday, March 13, 2017.

Photographer: Michael Nagle

The market for diabetes drugs is one of the most competitive in all of pharma. 

There are frequently many similar treatments available to treat a very large patient population, which gives insurers and pharmacy benefit managers method and motive to work hard to drive down prices. They've been succeeding, and will get more ammunition in the year to come.